Anti-BRAF (mutated V600E) Antibody [V600E/1322] - BSA and Azide free

Pe scurt

Descriere

Specificații

Brand

Antibodies

Mărime

100µg

Țintă

BRAF (mutated V600E)

Applications

ELISA

Reactivity

Human

Formulation

Supplied in 10mM Phosphate Buffered Saline; without Sodium Azide and carrier free.

Conjugate

Unconjugated

Host

Mouse

Clonality

Monoclonal

Product form

Liquid

Concentration

1 mg/ml

Purification

Protein A chromatography.

Isotype

IgG

Molecular weight

35 kDa (predicted)

Light chain

kappa

Clonă

V600E/1322

Imunogen

An eleven amino acid residue long synthetic peptide (aa596-606), corresponding to Cys-GLAT(E)KSRWSG from human BRAF protein. It was conjugated to KLH at the N-terminus.

Specificitate

The BRAF gene encodes a cytoplasmic serine-threonine kinase, which initiates the activation of the mitogen-activated protein kinase (MAPK) signalling pathway. The oncogenic mutations in the kinase region of BRAF gene result in constitutive activation of the MAPK signalling pathway, leading to increased cell proliferation, resistance to apoptosis and tumor progression. The most common of all activating BRAF mutations leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. The BRAF V600E mutation is an important predictive and prognostic biomarker. The BRAF V600E mutation is detected in approximately 8% of all solid tumours, including 45% of papillary thyroid carcinomas, 40-60% of melanomas, 5-15% of colorectal adenocarcinomas, 35% of serous low grade and borderline ovarian carcinomas, 1-3% of non-small cell lung cancers, and 5-7% of cholangiocarcinomas. Furthermore, the BRAF V600E mutation is found in 100% of hairy cell leukaemia, 54% Erdheim-Chester disease, 38% of Langerhans cell histocytoses and 60% of pleomorphic xanthoastrocytomas.

Storage

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

Documentație

• Fișă tehnică (PDF)se deschide pe site-ul producătorului